Robert Huddart
A5047234703- Testicular diseases and treatments
- Bladder and Urothelial Cancer Treatments
- Advanced Radiotherapy Techniques
- Urinary and Genital Oncology Studies
- Sarcoma Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Sexual Differentiation and Disorders
- Urologic and reproductive health conditions
- Neuroblastoma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Ovarian cancer diagnosis and treatment
- Radiomics and Machine Learning in Medical Imaging
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Sperm and Testicular Function
- Lung Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Urological Disorders and Treatments
- Glioma Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Multiple and Secondary Primary Cancers
- Advances in Oncology and Radiotherapy
- Cancer Genomics and Diagnostics
Royal Marsden Hospital
2016-2025
Royal Marsden NHS Foundation Trust
2016-2025
Institute of Cancer Research
2016-2025
Princess Margaret Cancer Centre
2023
National Health Service
2004-2022
Cancer Research UK
2002-2021
Royal London Hospital
2011-2021
Peter MacCallum Cancer Centre
2021
St Bartholomew's Hospital
2021
University College London
2009-2021
Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase inhibitor of FGFR1–4, has shown antitumor activity preclinical models phase 1 study involving patients FGFR alterations.
Radiotherapy is an alternative to cystectomy in patients with muscle-invasive bladder cancer. In other disease sites, synchronous chemoradiotherapy has been associated increased local control and improved survival, as compared radiotherapy alone.
Purpose: To assess the risk of cardiovascular morbidity and cardiac factors in long-term survivors testicular cancer according to treatment received. Patients Methods: All resident male patients registered United Kingdom between 1982 1992 attending for follow-up were eligible recruitment. completed a current health questionnaire underwent clinical review, along with hematologic, biochemical, hormonal profiles. For not under routine information was sought from their general practitioner...
The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose in patients localised prostate cancer. Preliminary findings reported after 5 years follow-up showed that escalated-dose improved biochemical progression-free survival. Based on the sample size calculation, we planned analyse overall survival when 190 deaths occurred; target has now been reached, a median 10 follow-up.RT01 phase 3, open-label, international, randomised controlled enrolling men...
The role of prophylactic antibacterial agents after chemotherapy remains controversial.We conducted a randomized, double-blind, placebo-controlled trial in patients who were receiving cyclic for solid tumors or lymphoma and at risk temporary, severe neutropenia (fewer than 500 neutrophils per cubic millimeter). Patients randomly assigned to receive either mg levofloxacin once daily matching placebo seven days during the expected neutropenic period. primary outcome was incidence clinically...
In November 2011, the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer (GCC) was held in Berlin, Germany. This third conference followed similar meetings 2003 (Essen, Germany) 2006 (Amsterdam, The Netherlands) [Schmoll H-J, Souchon R, Krege S et al. consensus diagnosis treatment germ-cell cancer: a report Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399; S, Beyer J, R second meeting group (EGCCCG): part I. Eur Urol 2008; 53: 478-496; II. 497-513]. A panel 56 60...
Prostate cancer might have high radiation-fraction sensitivity, implying a therapeutic advantage of hypofractionated treatment. We present pre-planned preliminary safety analysis side-effects in stages 1 and 2 randomised trial comparing standard radiotherapy.We did multicentre, study recruited men with localised prostate between Oct 18, 2002, Aug 12, 2006, at 11 UK centres. Patients were randomly assigned 1:1:1 ratio to receive conventional or high-dose intensity-modulated radiotherapy, all...
The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held 3-5 November 2016 in Paris, France. included a multidisciplinary panel of 36 leading experts the diagnosis and treatment (34 members attended conference; an additional two [CB K-PD] participated all preparatory work subsequent manuscript development). aim to develop detailed recommendations topics relating that are not covered detail current ESMO Clinical Practice Guidelines (CPGs) where...
BackgroundExpression of intrinsic markers tumour hypoxia and angiogenesis are important predictors radiotherapeutic, possibly surgical, outcome in several cancers. Extent localised prostate cancer is comparable to that other cancers, but few data exist on the association extent with treatment outcome. We aimed study predictive value cancer, both patients treated radiotherapy those surgically.MethodsWe applied a new, needle biopsy tissue microarray (TMA) technique diagnostic samples from men...